ZURICH (Reuters) – Swiss drugmaker Roche said trials showed its new blood cancer drug Gazyva failed to deliver significant improvements over an older medicine in people with an aggressive type of blood cancer, a blow in its fight against competition from biosimilars.
To learn more visit: Reuters: Health News
The post Roche receives blood cancer drug blow after Gazyva trial fails to meet endpoint appeared first on Online Medical Assistant Training Programs.
from WordPress https://onlinemedicalassistantprogramsedu.wordpress.com/2016/07/18/roche-receives-blood-cancer-drug-blow-after-gazyva-trial-fails-to-meet-endpoint/
No comments:
Post a Comment